Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria

Kidney International Reports（2023）

引用 10|浏览23

暂无评分

摘要

Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.

查看译文

关键词

BLyS/APRIL inhibitors,IgA Nephropathy,proteinuria,TACI-Fc fusion protein,telitacicept

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要